2016 Section 5 Green Book

29 / 236

24. Zivadinov R, Zorzon M, Monti Bragadin L, Pagliaro G, Cazzato G. Olfactory loss
in multiple sclerosis. J Neurol Sci . 1999;168(2):127-130.
25. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dys-
function in early stage treated and untreated idiopathic Parkinson’s disease.J Neu-
rol Neurosurg Psychiatry. 1992;55(2):138-142.
26. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and
treated Parkinson’s disease: possible implications for early diagnosis. Mov Disord.
2001;16(1):41-46.
27. Hummel T, Jahnke U, Sommer U, Reichmann H, Mu¨ller A. Olfactory function in
patients with idiopathic Parkinson’s disease: effects of deep brain stimulation in
the subthalamic nucleus. J Neural Transm. 2005;112(5):669-676.
28. Liberini P, Parola S, Spano PF, Antonini L. Olfaction in Parkinson’s disease: meth-
ods of assessment and clinical relevance. J Neurol. 2000;247(2):88-96.
29. Kesslak JP, Cotman CW, Chui HC, et al. Olfactory tests as possible probes for
detecting and monitoring Alzheimer’s disease. Neurobiol Aging. 1988;9(4):
399-403.
30. Serby MJ. Olfactory deficit in Alzheimer’s disease? Am J Psychiatry. 2001;158(9):
1534-1535.
31. O¨ zben T, Chevion M, eds. Frontiers in Neurodegenerative Disorders and Aging:
Fundamental Aspects, Clinical Perspectives and New Insights. Vol 358. Amster-
dam, the Netherlands: IOS Press; 2004. NATO Science Series, I: Life and Behav-
ioral Sciences.
32. Warner MD, Peabody CA, Flattery JJ, Tinklenberg JR. Olfactory deficits and Alz-
heimer’s disease. Biol Psychiatry. 1986;21(1):116-118.
33. Moberg PJ, Doty RL. Olfactory function in Huntington’s disease patients and at-
risk offspring. Int J Neurosci. 1997;89(1-2):133-139.
34. Henkin RI, Velicu I, Papathanassiu A. cAMP and cGMP in human parotid saliva:
relationships to taste and smell dysfunction, gender, and age. Am J Med Sci.
2007;334(6):431-440.
35. Henkin RI, Velicu I. Decreased parotid salivary cyclic nucleotides related to smell
loss severity in patients with taste and smell dysfunction. Metabolism. 2009;
58(12):1717-1723.
36. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus: relationships to taste and
smell dysfunction, gender and age. Clin Invest Med. 2008;31(2):E71-E77. http:
/ Accessed March 10, 2011.
37. Henkin RI, Velicu I. cAMP and cGMP in nasal mucus related to severity of smell
loss in patients with smell dysfunction. Clin Invest Med. 2008;31(2):E78-E84.
38. Henkin RI, Velicu I. Etiological relationships of parotid saliva cyclic nucleotides
in patients with taste and smell dysfunction. Arch Oral Biol. 2012;57(6):670-
677. Accessed January 20,
2012.
39. Henkin RI, Velicu I. Aetiological relationships of nasal mucus cyclic nucleotides
in patients with taste and smell dysfunction. J Clin Pathol. 2012;65(5):447-
451.
40. Henkin RI, Velicu I, Schmidt L. An open-label controlled trial of theophylline for
treatment of patients with hyposmia. Am J Med Sci. 2009;337(6):396-406.
41. Gudziol V, Hummel T. Effects of pentoxifylline on olfactory sensitivity: a post-
marketing surveillance study. Arch Otolaryngol Head Neck Surg. 2009;135
(3):291-295.
42. Henkin RI, Velicu I, Schmidt L. Relative resistance to oral theophylline treatment
in patients with hyposmia manifested by decreased secretion of nasal mucus
cyclic nucleotides. Am J Med Sci. 2011;341(1):17-22.
43. Weinberger M. Theophylline for treatment of asthma. J Pediatr. 1978;92(1):1-7.
44. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for
reappraisal? Eur Respir J . 1994;7(3):579-591.
45. Henkin RI. Comparative monitoring of oral theophylline treatment in blood se-
rum, saliva, and nasal mucus. Ther Drug Monit. 2012;34(2):217-221.
46. Church JA, Bauer H, Bellanti JA, Satterly RA, Henkin RI. Hyposmia associated
with atopy. Ann Allergy. 1978;40(2):105-109.
47. Henkin RI, Larson AL, Powell RD. Hypogeusia, dysgeusia, hyposmia, and dys-
osmia following influenza-like infection. Ann Otol Rhinol Laryngol. 1975;84
(5, pt 1):672-682.
48. Schechter PJ, Henkin RI. Abnormalities of taste and smell after head trauma.
J Neurol Neurosurg Psychiatry. 1974;37(7):802-810.
49. Henkin RI, Levy LM. Functional MRI of congenital hyposmia: brain activation to
odors and imagination of odors and tastes. J Comput Assist Tomogr . 2002;
26(1):39-61.
50. Henkin RI. Taste in man. In: Harrison D, Hinchcliffe R, eds. Scientific Founda-
tions of Otolaryngology. London, England: Wm Heinemann Medical Books Ltd;
1976:469-483.
51. Henkin RI, Schecter PJ, Friedewald WT, Demets DL, Raff MS. A double blind study
of the effects of zinc sulfate on taste and smell dysfunction. Am J Med Sci. 1976;
272(3):285-299.
52. Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res. 1992;9(1):1-9.
53. Al Suleimani YM, Walker MJ. Allergic rhinitis and its pharmacology. Pharmacol
Ther. 2007;114(3):233-260.
54. Watelet JB, Gillard M, Benedetti MS, Lelièvre B, Diquet B. Therapeutic manage-
ment of allergic diseases. Drug Metab Rev. 2009;41(3):301-343.
55. Djukanovic´ R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects
of theophylline on mucosal inflammation in asthmatic airways: biopsy results.
Eur Respir J. 1995;8(5):831-833.
56. Thorne RG, Emory CR, Ala TA, Frey WH II. Quantitative analysis of the olfactory
pathway for drug delivery to the brain. Brain Res. 1995;692(1-2):278-282.
57. Putcha L, Tietze KJ, Bourne DW, Parise CM, Hunter RP, Cintro´n NM. Bioavail-
ability of intranasal scopolamine in normal subjects. J Pharm Sci. 1996;85
(8):899-902.
58. Kubek MJ, Ringel I, Domb AJ. Issues in intranasal neuropeptide uptake. In: Ko-
biler D, Lustig S, Shapiro S, eds. Blood-Brain Barrier: Drug Delivery and Brain
Pathology. New York, NY: Springer; 2001:331.
59. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol.
2004;56(1):3-17.
60. Dorman DC, Brenneman KA, McElveen AM, Lynch SE, Roberts KC, Wong BA.
Olfactory transport: a direct route of delivery of inhaled manganese phosphate
to the rat brain. J Toxicol Environ Health A. 2002;65(20):1493-1511.
61. Reinhardt RR, Bondy CA. Insulin-like growth factors cross the blood-brain barrier.
Endocrinology. 1994;135(5):1753-1761.
62. Kastin AJ, PanW. Intranasal leptin: blood-brain barrier bypass (BBBB) for obesity?
Endocrinology. 2006;147(5):2086-2087.
63. Dahlin M, Bjo¨rk E. Nasal absorption of (S)-UH-301 and its transport into the ce-
rebrospinal fluid of rats. Int J Pharm. 2000;195(1-2):197-205.
64. Banks WA. The source of cerebral insulin.Eur J Pharmacol. 2004;490(1-3):5-12.
65. Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier insulin receptor.
J Neurochem. 1985;44(6):1771-1778.
66. Henkin RI. Intranasal insulin: from nose to brain.Nutrition. 2010;26(6):624-633.
67. Dahlin M, Jansson B, Bjo¨rk E. Levels of dopamine in blood and brain following
nasal administration to rats. Eur J Pharm Sci. 2001;14(1):75-80.
68. Dahlin M, Bergman U, Jansson B, Bjo¨rk E, Brittebo E. Transfer of dopamine in
the olfactory pathway following nasal administration in mice. Pharm Res. 2000;
17(6):737-742.
69. Evans J, Hastings L. Accumulation of Cd(II) in the CNS depending on the route
of administration: intraperitoneal, intratracheal, or intranasal. FundamAppl Toxicol.
1992;19(2):275-278.
70. Chow HS, Chen Z, Matsuura GT. Direct transport of cocaine from the nasal cav-
ity to the brain following intranasal cocaine administration in rats. J Pharm Sci.
1999;88(8):754-758.
71. Henkin RI. Intranasal delivery to the brain. Nat Biotechnol. 2011;29(6):480. doi:
10.1038/nbt.1866.
72. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332(13):868-
875.
73. Bush A. Practice imperfect: treatment for wheezing in preschoolers.N Engl J Med.
2009;360(4):409-410.
74. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: advances in migraine
treatment. Neurology. 2003;61(8)(suppl 4):S27-S30.
75. Zheng YQ, Wei W, Shen YX, Dai M, Liu LH. Oral and nasal administration of chicken
type II collagen suppresses adjuvant arthritis in rats with intestinal lesions in-
duced by meloxicam. World J Gastroenterol. 2004;10(21):3165-3170.
76. Mattsson LA, Christiansen C, Colau JC, et al. Clinical equivalence of intranasal
and oral 17 -estradiol for postmenopausal symptoms. Am J Obstet Gynecol.
2000;182(3):545-552.
77. Ziai F, Walter R, Rosenthal IM. Treatment of central diabetes insipidus in adults
and children with desmopressin. Arch Intern Med. 1978;138(9):1382-1385.
78. Fjellestad-Paulsen A, Wille S, Harris AS. Comparison of intranasal and oral des-
mopressin for nocturnal enuresis. Arch Dis Child. 1987;62(7):674-677.
ARCH OTOLARYNGOL HEAD NECK SURG/VOL 138 (NO. 11), NOV 2012
7